PD 407824

Confirm delete?

PD 407824

Zoom

Cat No: 25989

Biochemicals - Kinase Inhibitors

PD 407824 is an inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively).{37766} It is selective for Chk1 and WEE1 over PKC (IC50 = 3.4 µM), Cdk4 (IC50 = 3.75 µM), as well as c-Src and the PDGF and FGF receptors (IC50s = ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

9-hydroxy-4-phenyl-pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione

Correlated keywords:

PD407824 0407824 PD0407824 chk-1 wee-1 cSrc SKOV-3 SKOV3 OVCAR3 A-2780 BMP-4 SK-OV3 Cdk-4 C2-C12 C-2C12 C2C-12 C-2C-12

Product Overview:
PD 407824 is an inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively).{37766} It is selective for Chk1 and WEE1 over PKC (IC50 = 3.4 µM), Cdk4 (IC50 = 3.75 µM), as well as c-Src and the PDGF and FGF receptors (IC50s = >50 µM for all), and other Cdks (IC50s = >50 µM).{37767} PD 407824 sensitizes SK-OV-3 and OVCAR-3 ovarian cancer cells, as well as cisplatin-resistant A2780cis cells, to cisplatin when used at a concentration of 0.5 µM.{37768} It also sensitizes C2C12 myoblasts to bone morphogenic protein 4 (BMP4) and, when used in combination with BMP4, inhibits myotube formation and induces myoblasts to differentiate into mature osteoblasts.{37769} PD 407824, in combination with BMP4, induces human embryonic stem cells to differentiate into cells with mesoderm or cytotrophoblast stem cell lineages.

Size	1 mg
Shipping	dry ice
CAS Number	622864-54-4
Molecular Formula	C₂₀H₁₂N₂O₃
SMILES	O=C1NC(C2=C1C(C(C=C(O)C=C3)=C3N4)=C4C=C2C5=CC=CC=C5)=O
Molecular Weight	328,3
Formulation	A solid
Purity	≥98%
Custom Code	2907.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.